Big pharma, Partnering, Pharma

Pharma news: GSK pays $90 million in Avandia settlement

Posted on 20 November 2012

Tags: , ,

GlaxoSmithKline, a top pharma company, topped the pharma news charts when imposed with allegations on illegal marketing of its diabetes drug, Avadia.

However GSK has agreed to pay $90 million to resolve all its allegations by prosecutors, in 38 states that the pharmaceutical company illegally marketed the diabetes drug Avandia, a onetime multibillion-dollar-a-year seller whose sales plummeted after the drug was linked to heart-attack risks.

As reported in the pharma news report, Glaxo and the states reached a settlement shortly thereafter, according to a statement Thursday from Oregon's attorney general, who helped lead the investigation.

For further deal information visit Current Agreements (subscription required)


Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies

Report: Co-promotion and Co-marketing Partnering Terms and Agreements

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply